Primary hyperparathyroidism – ways to solve
AbstractPrimary hyperparathyroidism (PHPT) is a rather urgent problem due to the initial pathological changes in the parathyroid glands (PTG). They are accompanied by unregulated production of parathyroid hormone into the blood, an increase in serum calcium levels. Epidemiological data indicate a connection between this pathology and factors such as gender, age, geographic location, race, level of development of medicine. The clinical manifestations of PHPT are quite multifaceted, first of all, the changes affect the main target organs: kidneys, skeletal system, gastrointestinal tract. Recent studies confirm the fact of the relationship between neuropsychiatric disorders and PHPT, which proves the role of the studied pathology in reducing the quality of life.
The choice of this or that diagnostic procedure is rather difficult and for an accurate determination of the diagnosis of PHPT, an integrated approach is required using existing laboratory and instrumental techniques, the analysis of which will make it more likely to verify the pathology of the parathyroid glands. The choice of patient management tactics is determined by the clinical course of the disease, the data of objective and laboratory-instrumental research methods, and the patient’s personality characteristics.
The most justified is surgical treatment, the effectiveness of which reaches 95–99% with a fairly low frequency of complications.
Improving the personalized approach to surgical intervention, taking into account the achievements and innovations in practical medicine of recent years, will contribute not only to improving treatment results, but also to improving the quality of life of patients.
Keywords:parathyroid hormone; parathyroid glands; primary hyperparathyroidism
Funding. The study had no sponsor support.
Conflict of interest. The author declarse no conflict of interest.
For citation: Niyazova N.F. Primary hyperparathyroidism – ways to solve. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2023; 12 (1): 39–47. DOI: https://doi.org/10.33029/2304-9529-2023-12-1-39-47 (in Russian)
References
1. Guo Y., Wang Q., Lu C., et al. New parathyroid function index for the differentiation of primary and secondary hyperparathyroidism: A case-control study. BMC Endocr Disord. 2020; 20: 5. DOI: https://doi.org/10.1186/s12902-019-0487-8
2. Dandurand K., Ali D.S., Khan A.A. Primary hyperparathyroidism: A narrative review of diagnosis and medical management. J Clin Med. 2021; 10 (8): 1604. DOI: https://doi.org/10.3390/jcm10081604 PMID: 33918966; PMCID: PMC 8068862.
3. Bilezikian J.P. Primary hyperparathyroidism. J Clin Endocrinol Metab. 2018; 103 (11): 3993–4004. DOI: https://doi.org/10.1210/jc.2018-01225
4. Liu H., Luo K., Liao S., Tang H., Mo J., Xie T., et al. Diagnosis and treatment of primary hyperparathyroidism with pathological fracture of the limbs: A retrospective observational study. Medicine (Baltimore). 2022; 101 (33): e29966. DOI: https://doi.org/10.1097/MD.0000000000029966
5. Dedov I.I., Mel’nichenko G.A., Mokrysheva N.G., Rozhinskaya L.Y., Kusnetsov N.S., Pigarova E.A., et al. Primary hyperparathyroidism: the clinical picture, diagnostics, differential diagnostics, and methods of treatment. Problemy endokrinologii [Problems of Endocrinology]. 2016; 62 (6): 40–77. DOI: https://doi.org/10.14341/probl201662640-77 (in Russian)
6. Darbà J., Marsà A. Epidemiology and management of parathyroid gland disorders in Spain over 15 years: A retrospective multicentre analysis. PLoS One. 2020; 15 (3): e0230130. DOI: https://doi.org/10.1371/journal.pone.0230130
7. Wihlborg A., Bergström K., Gerdhem P., et al. Parathyroid hormone disturbances in postmenopausal women with distal forearm fracture. World J Surg. 2022; 46: 128–35. DOI: https://doi.org/10.1007/s00268-021-06331-w
8. Rozhinskaya L.Y., Gronskaya S.A., Mamedova E.O., Belaya Z.E., Mel’nichenko G.A. The comparative efficiency of denosumab treatment in patients with postmenopausal osteoporosis, primary hyperparathyroidism and glucocorticoid-induced osteoporosis in real clinical practice. Osteoporoz i osteopatii [Osteoporosis and Osteopathies]. 2020; 23 (1): 4–13. DOI: https://doi.org/10.14341/osteo12415 (in Russian)
9. Fieber J., Goodsell K., Kelz R.R., Ermer J.P., Wirtalla C., Fraker D.L., et al. Racial disparities in primary hyperparathyroidism. World J Surg. 2021; 45 (1): 180–7. DOI: https://doi.org/10.1007/s00268-020-05791-w Epub 2020 Sep 25. PMID: 32978665; PMCID: PMC 7906108.
10. Al-Saleh Y., AlSohaim A., AlAmoudi R., et al. Primary hyperparathyroidism in Saudi Arabia revisited: A multi-centre observational study. BMC Endocr Disord. 2022; 22: 155. DOI: https://doi.org/10.1186/s12902-022-01059-7
11. Brandi M.L. (ed.). Parathyroid Disorders. Focusing on Unmet Needs (Vol. 51. Frontiers of Hormone Research). Basel: Karger, 2019. P. 13–22. DOI: https://doi.org/10.1159/000491035
12. Yanevskaya L.G., Karonova T.L., Sleptsov I.V., Boriskova M.E., Bakhtiyarova A.R., Ivanova E.V., et al. Primary hyperparathyroidism: Clinical forms and their features. Retrospective study. Klinicheskaya i eksperimental’naya tireodologiya [Clinical and Experimental Thyroidology]. 2019; 15 (1): 19–29. DOI: https://doi.org/10.14341/ket10213 (in Russian)
13. Agency on Statistics under the President of the Republic of Tajikistan. URL: https://www.stat.tj/tj/database-socio-demographic-sector (date of access August 05, 2021). (in Russian)
14. Papadakis M., Weyerbrock N., Zirngibl H., et al. Correlation of perioperative biochemical variables with single adenoma weight in patients with primary hyperparathyroidism. BMC Surg. 2020; 20: 303. DOI: https://doi.org/10.1186/s12893-020-00922-5
15. Gorbacheva A.M., Eremkina A.K., Mokrysheva N.G. Hereditary syndromal and nonsyndromal forms of primary hyperparathyroidism. Problemy endokrinologii [Problems of Endocrinology]. 2020; 66 (1): 23–34. DOI: https://doi.org/10.14341/probl10357 (in Russian)
16. Marx S.J. New concepts about familial isolated hyperparathyroidism. J Clin Endocrinol Metab. 2019; 104 (9): 4058–66. DOI: https://doi.org/10.1210/jc.2018-02789
17. Mamedova E.O., Mokrysheva N.G., Rozhinskaya L.Y. Hereditary forms of primary hyperparathyroidism. Osteoporoz i osteopatii [Osteoporosis and Osteopathies]. 2018; 21 (2): 23–9. DOI: https://doi.org/10.14341/osteo9877 (in Russian)
18. Won E., Kim Y. An oldie but goodie: Lithium in the treatment of bipolar disorder through neuroprotective and neurotrophic mechanisms. Int J Mol Sci. 2017; 18 (12): 2679.
19. Mokrysheva N.G., Eremkina A.K., Mirnaya S.S., Krupinova J.A., Voronkova I.A., Kim I.V., et al. The clinical practice guidelines for primary hyperparathyroidism, short version. Problemy endokrinologii [Problems of Endocrinology]. 2021; 67 (4): 94–124. DOI: https://doi.org/10.14341/probl12801 (in Russian)
20. Gorobeiko M., Dinets A., Pominchuk D., Abdalla K., Prylutskyy Y., Hoperia V. Challenges of differential diagnosis between primary hyperparathyroidism and bone metastases of breast cancer. Clin Med Insights Case Rep. 2022; 15: 11795476221125136. DOI: https://doi.org/10.1177/11795476221125136 PMID: 36159181; PMCID: PMC 9493671.
21. Ikromov T. Sh. Optimization of intensive care and anesthesia care in children with bilateral urolithiasis complicated by chronic kidney disease: Diss. Dushanbe, 2017. (in Russian)
22. Abdulloev S.M. Clinical and epidemiological features and risk factors for the development of chronic kidney disease in the Republic of Tajikistan: Diss. Dushanbe, 2019. (in Russian)
23. Nezhad F.A., Payab M., Nayebandi S., Hasani-Ranjbar S. Jaw tumor in recurrent primary hyperparathyroidism: A case report. Int J Surg Case Rep. 2018; 52: 54–8. DOI: https://doi.org/10.1016/j.ijscr.2018.09.035
24. Mihashi I., Ishii K., Ogawa Y., Uchida A., Hara H., Tamaoka A. Normocalcemic primary hyperparathyroidism presenting with muscle weakness and body pain. Intern Med. 2021; 60 (6): 953–6. DOI: https://doi.org/10.2169/internalmedicine.6131-20 Epub 2020 Nov 30. PMID: 33250466; PMCID: PMC 8024951.
25. Romagnoli C., Brandi M.L. Muscle physiopathology in parathyroid hormone disorders. Front Med (Lausanne). 2021; 8: 764346. DOI: https://doi.org/10.3389/fmed.2021.764346 PMID: 34746197; PMCID: PMC 8569254.
26. Mokrysheva N.G., Eremkina A.K., Kovaleva E.V., Krupinova J.A., Vikulova O.K. Modern problems of hyper- and hypoparathyroidism. Terapevticheskiy arkhiv [Therapeutic Archive]. 2021; 93 (10): 1149–54. DOI: https://doi.org/10.26442/00403660.2021.10.201109 (in Russian)
27. Otsuki K., Izuhara M., Miura S., Yamashita S., Nagahama M., Hayashida M., et al. Psychosis in a primary hyperparathyroidism patient with mild hypercalcemia: A case report. Medicine (Baltimore). 2021; 100 (12): e25248. DOI: https://doi.org/10.1097/MD.0000000000025248
28. Poyarkova V.O., Runova G.E., Fadeev V.V. Neurocognitive aspects of hyperparathyroidism. Ozhirenie i metabolism [Obesity and Metabolism]. 2019; 16 (1): 7–11. DOI: https://doi.org/10.14341/omet9507 (in Russian)
29. Webb S.M., Puig-Domingo M., Villabona C., Muñoz-Torres M., Marazuela M., Fernández D., et al. Validation of PHPQoL, a disease-specific quality-of-life questionnaire for patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2016; 101 (4): 1571–8. DOI: https://doi.org/10.1210/jc.2015-3094
30. Bryzgalina S.M., Kashirina E.P., Shcherenko A.G., Koroleva Yu.B., Vylegzhanina O.V., Kashirina E. Zh. Difficulties in diagnosing primary hyperparathyroidism during pregnancy. Sovremennye problemy nauki i obrazovaniya [Modern Problems of Science and Education]. 2019; (4). (in Russian)
31. Berger C., Almohareb O., Langsetmo L., Hanley D.A., Kovacs C.S., Josse R.G., et al. Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers. Clin Endocrinol (Oxf). 2015; 82: 359–68. DOI: https://doi.org/10.1111/cen.12569
32. Alore E.A., Suliburk J.W., Ramsey D.J., et al. Diagnosis and management of primary hyperparathyroidism across the Veterans Affairs health care system. JAMA Intern Med. 2019; 179 (9): 1220–7. DOI: https://doi.org/10.1001/jamainternmed.2019.1747
33. Schini M., Jacques R.M., Oakes E., Peel N.F.A., Walsh J.S., Eastell R. Normocalcemic hyperparathyroidism: Study of its prevalence and natural history. J Clin Endocrinol Metab. 2020; 105 (4): e1171–86. DOI: https://doi.org/10.1210/clinem/dgaa084 Epub 2020 Feb 19. PMCID: PMC 7069345.
34. Beysel S., Caliskan M., Kizilgul M., et al. Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism. BMC Cardiovasc Disord. 2019; 19: 106. DOI: https://doi.org/10.1186/s12872-019-1093-4
35. McWade M.A., Thomas G., Nguyen J.Q., Sanders M.E., Solórzano C.C., Mahadevan-Jansen A. Enhancing parathyroid gland visualization using a near infrared fluorescence-based overlay imaging system. J Am Coll Surg. 2019; 228 (5): 730–43.
36. Slashchuk K. Yu., Degtyarev M.V., Rumyantsev P.O., Troshina E.A., Mel’nichenko G.A. Imaging methods of the parathyroid glands in primary hyperparathyroidism. Literature review. Endokrinnaya khirurgiya [Endocrine Surgery]. 2019; 13 (4): 153–74. DOI: https://doi.org/10.14341/serg12241 (in Russian)
37. Tsai K., Liang T.Z., Grant E.G., Swanson M.S., Barnett B. Optimal imaging modality for diagnosis of parathyroid adenoma: Case report and review of the literature. J Clin Transl Endocrinol Case Rep. 2020; 17: 100065. DOI: https://doi.org/10.1016/j.jecr.2020.100065
38. Shen J., Wu Q., Wang Y. The role of ultrasound in the diagnosis of the coexistence of primary hyperparathyroidism and non-medullary thyroid carcinoma. BMC Med Imaging. 2019; 19: 7. DOI: https://doi.org/10.1186/s12880-019-0306-8
39. Dekorsy F.J., Beyer L., Spitzweg C., Schmidmaier R., Todica A., Trupka A., et al. Preoperative imaging with [18F]-fluorocholine PET/CT in primary hyperparathyroidism. J Clin Med. 2022; 11: 2944. DOI: https://doi.org/10.3390/jcm11102944
40. Lezaic L., Rep S., Sever M.J., Kocjan T., Hocevar M., Fettich J. 18F-fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: A pilot study. Eur J Nucl Med Mol Imaging. 2014; 41: 2083–9.
41. Schwartz I.E., Capra G.G., Mullin D.P., et al. Parathyroid computed tomography angiography: Early experience with a novel imaging technique in primary hyperparathyroidism. Otolaryngol Head Neck Surg. 2019; 161 (2): 251–6. DOI: https://doi.org/10.1177/0194599819842106
42. Tassone F., Guarnieri A., Castellano E., et al. Parathyroidectomy halts the deterioration of renal function in primary hyperparathyroidism. J Clin Endocrinol Metab. 2015; 100 (8): 3069–73. DOI: https://doi.org/10.1210/jc.2015-2132
43. Zhang J.L.H., Appelman-Dijkstra N.M., Fu E.L., et al. Practice variation in the treatment of patients with renal hyperparathyroidism: A survey-based study in the Netherlands. BMC Nephrol. 2021; 22: 150. DOI: https://doi.org/10.1186/s12882-021-02361-7
43. Al-Daghri N.M., Yakout S., Aljohani N., Al-Saleh Y., Al-Attas O.S., Reginster J.-Y., et al. Vitamin D Status and its correlation with parathyroid hormone level among population in Riyadh, Saudi Arabia. J King Saud Univ Sci. 2020; 32 (3): 2016–9. DOI: https://doi.org/10.1016/j.jksus.2020.02.002
43. Xia W., Zhang J., Shen W., Zhu Z., Yang Z., Li X. A rapid intraoperative parathyroid hormone assay based on the immune colloidal gold technique for parathyroid identification in thyroid surgery. Front Endocrinol (Lausanne). 2020; 11: 594745. DOI: https://doi.org/10.3389/fendo.2020.594745
44. Bilezikian J.P., Khan A.A., Clarke B.L., Mannstadt M., Potts J.T., Brandi M.L. The Fifth International Workshop on the evaluation and management of primary hyperparathyroidism. J Bone Miner Res. 2022; 37 (11): 2290–2. DOI: https://doi.org/10.1002/jbmr.4670
45. Bobanga I.D., McHenry C.R. Is intraoperative parathyroid hormone monitoring necessary for primary hyperparathyroidism with concordant preoperative imaging? Am J Surg. 2017; 213 (3): 484–8. DOI: https://doi.org/10.1016/j.amjsurg.2016.11.035
46. Shawky M., Abdel Aziz T., Morley S., et al. Impact of intraoperative parathyroid hormone monitoring on the management of patients with primary hyperparathyroidism. Clin Endocrinol (Oxf). 2019; 90 (2): 277–84. DOI: https://doi.org/10.1111/cen.13882
47. Khan A.A., Bilezikian J.P., Brandi M.L., Clarke B.L., Potts J.J., Mannstadt M. The Second International Workshop on the evaluation and management of hypoparathyroidism. J Bone Miner Res. 2022; 37 (12): 2566–7. DOI: https://doi.org/10.1002/jbmr.4671
48. Ferraro V., Sgaramella L.I., Di Meo G., et al. Current concepts in parathyroid carcinoma: A single centre experience. BMC Endocr Disord. 2019; 19: 46. DOI: https://doi.org/10.1186/s12902-019-0368-1